News & Updates
Filter by Specialty:
KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer
Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.
KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer
05 Aug 2024
Dostarlimab plus chemo extends survival in advanced/recurrent endometrial cancer
Treatment with dostarlimab combined with carboplatin‒paclitaxel significantly improves overall survival (OS) among patients with primary advanced or recurrent endometrial cancer (EC), with no new safety signals, results of the RUBY trial have shown.
Dostarlimab plus chemo extends survival in advanced/recurrent endometrial cancer
02 Aug 2024
MIRV treatment effects sustained in PROC despite dose modifications
In a post hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial, mirvetuximab soravtansine (MIRV) continues to demonstrate clinically meaningful improvements in survival and objective response rate (ORR) in women with platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha (FRα) expression who necessitated dose modifications.
MIRV treatment effects sustained in PROC despite dose modifications
02 Aug 2024
Long-term semaglutide reduces diabetes risk
In a prespecified secondary analysis of the SELECT trial, long-term treatment with semaglutide allows more patients with prediabetes to regress to normoglycaemia while reducing progression to diabetes in some patients. However, semaglutide does not slow glycaemic progression over time.